Life Sciences Catalyst Program
GINOP Plus-2.1.5-26
Up to HUF 3 Billion in Funding for Healthcare Research and Development Projects
CHECK MY ELIGIBILITYProgramme Objective
A new funding opportunity is becoming available for small and medium-sized enterprises (SMEs) operating in Hungary’s healthcare industry under the GINOP Plus-2.1.5-26 – Life Sciences Catalyst Program. With a total budget of HUF 15 billion, the programme supports the development of innovative medical devices and early-stage clinical trials of drug candidates. Eligible businesses can apply for non-repayable grants ranging from HUF 300 million to HUF 3 billion, with a project implementation period of up to 30 months.
Applications can be submitted between 5 January and 2 March 2027. While the programme offers substantial funding opportunities, it also sets strict scientific, technological and research and development requirements. Companies considering an application should therefore begin their preparations well in advance.
GINOP Plusz-2.1.5-26: HUF 15 Billion to Support Healthcare Innovation
The GINOP Plus-2.1.5-26 funding programme aims to facilitate healthcare developments that demonstrate significant scientific and technological novelty while supporting the future commercialisation of research results.
The programme primarily focuses on projects that address genuine unmet clinical needs and offer innovative solutions capable of improving diagnostic, preventive or therapeutic opportunities.
The call supports two main development areas:
- Medical device development (Component A): Research and development of innovative medical devices based on non-biotechnological methods.
- Drug development (Component B): Implementation of Phase I clinical trials of drug candidates, with particular emphasis on safety assessments associated with first-in-human administration.
Of the total HUF 15 billion funding allocation, HUF 10 billion is earmarked for projects implemented in Budapest, while the remaining HUF 5 billion is allocated to projects in Hungary’s less developed regions.
Up to HUF 3 Billion in Non-Repayable Grants
Under GINOP Plus-2.1.5-26, eligible applicants can request funding ranging from HUF 300 million to HUF 3 billion.
The main financing conditions are summarised below:
| Funding parameter | Key information |
| Call reference | GINOP Plus-2.1.5-26 |
| Programme | Life Sciences Catalyst Program |
| Total programme budget | HUF 15 billion |
| Available grant amount | HUF 300 million – HUF 3 billion |
| Form of support | Non-repayable grant |
| Advance payment | Up to 30%, maximum HUF 900 million |
| Project implementation | Maximum 30 months |
| Project location | Throughout Hungary |
| Application period | 5 January – 2 March 2027 |
The applicable aid intensity depends on several factors, particularly the size of the applicant company, the type of research and development activity and the relevant State aid regulations.
Applicants must provide their own financial contribution to the project. Under the applicable R&D aid conditions, industrial research requires a minimum own contribution of 20%, while experimental development requires at least 40%.
An advance payment of up to 30% of the awarded grant may also be requested, subject to a maximum limit of HUF 900 million.
What Types of Projects Are Eligible Under GINOP Plus-2.1.5-26?
Medical Device Development – Component A
Component A supports the development of innovative medical devices based on non-biotechnological methods that address significant clinical needs.
Funding may be available for the development of medical technologies intended for diagnostic, preventive, therapeutic and other healthcare applications.
The programme exclusively supports the development of devices classified within Classes IIa, IIb or III under the Medical Device Regulation (MDR), or Classes B, C or D under the In Vitro Diagnostic Medical Devices Regulation (IVDR).
Eligible activities include:
- Experimental development.
- Industrial (applied) research.
- Obtaining the relevant medical device certification.
- Activities supporting the implementation of the research and development project.
The development must start at a minimum of Technology Readiness Level (TRL) 3, with activities at this level already commenced, and reach at least completed TRL 7 by the end of the project.
An additional important requirement for Component A is the possession of an R&D qualification issued by the Hungarian National Research, Development and Innovation Office (NRDI Office).
Drug Development and Phase I Clinical Trials – Component B
Component B supports the early clinical development of drug candidates, providing funding for the implementation of Phase I clinical trials.
The objective is to enable drug development projects to progress through the safety assessments associated with first-in-human administration, establishing the foundation for subsequent clinical development stages.
Eligible activities include:
- Experimental development.
- Conducting clinical trial authorisation procedures.
- Related activities supporting research and development.
Under Component B, projects must start at a minimum of completed TRL 5 and achieve at least completed TRL 6 by the end of implementation.
One of the key requirements for project completion is the preparation of a Phase I clinical study report necessary to support the initiation of Phase II clinical trials.
Who Can Apply for GINOP Plus-2.1.5-26 Funding?
The programme is primarily available to small and medium-sized enterprises operating in the healthcare industry.
Companies applying independently must meet several eligibility requirements, including:
- Having at least two completed, full financial years.
- Employing an average statistical headcount of at least six employees during the most recently completed full financial year.
- Having a registered office in Hungary or an eligible Hungarian branch office.
- Maintaining double-entry bookkeeping.
- Having at least one of the healthcare-related TEÁOR business activities specified in the call registered before the relevant deadline.
Eligible business activities include pharmaceutical manufacturing, research and experimental development in natural sciences and engineering, medical device manufacturing, and certain diagnostic imaging and medical laboratory services.
Consortium applications are also permitted, with a maximum of three participating organisations. In such cases, the consortium leader must be an eligible healthcare industry SME with an average statistical headcount of at least three employees in its most recently completed full financial year.
Other enterprises, research institutions and eligible research and knowledge-dissemination organisations may participate as consortium partners.

Strict Scientific and Research Staffing Requirements
One of the distinguishing features of GINOP Plus-2.1.5-26 is that an innovative development concept alone is not sufficient to secure funding. Applicants must demonstrate the scientific and technological justification of their project, the relevance of the clinical need being addressed and the potential for commercial exploitation.
The call also establishes specific requirements regarding research personnel.
Throughout project implementation, beneficiaries must employ at least one researcher or developer holding a PhD degree relevant to the project’s field of expertise, working a minimum of 20 hours per week.
In addition, the project must employ at least one female researcher, developer, technician or research support staff member for a minimum of six months during the implementation period, also working at least 20 hours per week.
Another key requirement is that beneficiaries must obtain accredited certification under the ISO 56001:2024 Innovation Management System standard by the physical completion of the project.
Intellectual property obligations may also apply to the developments. Where applicants do not already hold the relevant industrial property protection or have an application pending at the time of submission, they must fulfil the applicable intellectual property requirements within 24 months following project completion.
When Can GINOP Plusz-2.1.5-26 Applications Be Submitted?
The application submission period is:
5 January 2027, 9:00 AM – 2 March 2027, 10:00 AM
Applications must be submitted electronically through the EPTK application system available on the official Hungarian funding portal, palyazat.gov.hu.
Companies are advised to begin preparing their applications well in advance, as the process may require substantial scientific, technical and financial documentation.
Particular attention should be paid to obtaining the required NRDI Office R&D qualification under Component A, substantiating the project’s Technology Readiness Levels, demonstrating clinical needs and commercial potential, and planning the necessary research personnel capacity.
Why Companies Should Start Preparing for GINOP Plus-2.1.5-26 Now
The GINOP Plus-2.1.5-26 – Life Sciences Catalyst Program represents a significant funding opportunity for healthcare companies planning to develop innovative medical devices or conduct early-stage clinical trials of drug candidates.
With non-repayable grants of up to HUF 3 billion, the programme could help businesses implement large-scale research and development projects with substantial scientific and technological added value.
However, the funding scheme includes complex eligibility, R&D, employment and certification requirements. A thorough preliminary assessment of the proposed project and a detailed review of the application conditions are therefore particularly important.
Is your company planning a medical device development project or an early-stage pharmaceutical research programme? Contact our expert team to assess your project’s preliminary eligibility, explore the available funding opportunities and identify the key steps required for successful application preparation.
Important: This information is based on the provided GINOP Plusz-2.1.5-26 Call for Proposals. The programme conditions may be amended. According to the call, the relevant European Union funding was blocked at the time of publication, meaning that applications may be placed on a reserve list. The official call documentation in force at the time of application submission shall always prevail.
BUSINESS SUCCESS AT EVERY SCALE
MAXIMIZE YOUR GRANT RESULTS
WITH IBSH'S HELP
0
Free consultation on subsidy opportunities
ibsh cooperation
1
state aid perspective due diligence of the company and designation of dedicated ibsh contact
2
setting up an eligible project, submit the subsidy application
3
communication with the managing body and the donor
4
preparing the financial and monitoring reports

THE UNIQUENESS OF IBSH
Market-leading experience gained on the donor’s side
Strategic advantage through stable professional relationships
Commitment to professional responsibility and fostering long-term partnerships
Let's work together to find the best solution for your company
Are you ready to leverage the opportunities provided by government support and grants? Fill out our form and get in touch with our experts for more details!
"*" indicates required fields
